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Summary
Objective: To better understand the clinical characteristics of soft tissue infections caused by
Shewanella in humans.
Methods: We report a case of Shewanella soft tissue infection and review the English literature
from a search of PubMed.
Results: A total of 27 adults (mean age 61.1  16.0 years) with soft tissue infections caused by
Shewanella were included for analysis. Limb involvement was found in 22 (81.5%) patients, while
scalp, face, perineum, lacrimal sac, and abdominal wall involvement were each found in one
patient. Chronic ulcer over the leg (14 cases (51.9%)), steroid use (four cases (14.8%)), and liver
cirrhosis (three cases (11.1%)) were the major underlying conditions. Shewanella bacteremia was
found in 14 out of 22 patients with soft tissue infections involving the limbs. Two patients died of
septicemia, giving a mortality rate of 7.4%.
Conclusions: Shewanella soft tissue infections usually develop in immunocompromised patients
with a preexisting cutaneous ulcer (particularly over the legs) after marine environment or
seawater exposure. In view of the possible catastrophic consequences, education on the
prevention of Shewanella soft tissue infections in at-risk people (e.g., the immunocompromised
or elderly with a cutaneous ulcer) relating the need to avoid exposure to the marine environment
or seawater may be of importance.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +886 7 7317123x8304;
fax: +886 7 7322402.
E-mail address: 88b0@adm.cgmh.org.tw (J.-W. Liu).
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Shewanella spp are motile Gram-negative bacilli with the
major phenotypic characteristic of production of largePublished by Elsevier Ltd. All rights reserved.
e120 M.-S. Tsai et al.amounts of hydrogen sulfide (H2S) in the butt of triple sugar
iron agar.1 Shewanella algae and Shewanella putrefaciens
are frequently found in non-human sources such as the
marine environment and foodstuffs, yet are opportunistically
pathogenic for humans.1
S. putrefaciens was once believed to be the major human
pathogenic species in the genus Shewanella, and authors in
most of the earlier reports on Shewanella human infections
attributed the etiology to S. putrefaciens.2 The taxon S. alga
was previously considered one biogroup of the genetically
heterogeneous S. putrefaciens species.3 In 1990, S. alga was
first recovered from red algae and was proposed to be a
tetrodotoxin-producing microbe.4 A subsequent study dis-
closed that the high G+C content in the previously recognized
S. putrefaciens isolates were genetically related to S. alga,
and most of the clinical S. putrefaciens isolates should there-
fore be reclassified as S. alga.5 In 1997, S. alga was renamed
S. algae.6 It is likely that>80% of clinical Shewanella isolates
in human infections are S. algae.2
Although S. algae was recognized as a new species in
1992,5 misidentification of S. algae as S. putrefaciens has
persisted ever since. These misidentifications have resulted
from the failure of both conventional phenotypic character-
istic testing and commercialized bacterial identification sys-
tems (e.g., ID 32 GN, and VITEK) in differentiating S.
putrefaciens from S. algae. In humans, soft tissue infections
are mostly encountered among infections reported to be
caused by Shewanella species.2 To better understand clinical
characteristics of soft tissue infections caused by Shewanella
in humans, we report a case of severe soft tissue infection
caused by S. algae in an immunocompromised adult and
review the literature.
Case report
A 42-year-old man with an underlying hepatitis B-related
liver cirrhosis was hospitalized because of fever and a swollen
left leg. He had injured his left leg 2 days earlier when he was
handling a seawater fish in preparation for his dinner. Some
skin lesions developed when his leg was stuck by the spinous
dorsal fin of the fish, and he tried to clean the oozing blood
from the damaged skin by flushing it with the water in which
the fish had been immersed before. Local heat and swelling
over his left leg soon developed, followed by fever and rigors.
Upon admission, he was acutely ill; his body temperature was
39.8 8C, and blood pressure was 90/60 mmHg. Physical exam-
ination revealed an extremely swollen left leg with edema-
tous dark red to purple-colored skin, and some hemorrhagic
bullae on the soft tissue over the distal end of the left leg and
the left ankle joint.
Blood tests revealed that his peripheral leukocyte count
was 2.7  109/l (normal 3.9—10.6  109/l) with the presence
of band-form cells and metamyelocytes, and his platelet
count was 37  109/l (normal 150—400  109/l). C-reactive
protein was 70.1 mg/l (normal <5 mg/l), aspartate amino-
transferase was 146 (normal <37 U/l), alanine aminotrans-
ferase was 55 U/l (normal <40 U/l), and serum creatinine
was 1.8 mg/dl (normal 0.4—1.4 mg/dl). A computed tomo-
graphy revealed severe edematous changes of the subcuta-
neous tissue andmuscles in the left leg. Under the impression
of necrotizing fasciitis and septic shock, parenteral ceftriax-
one (2 g/day) and oral doxycycline (200 mg/day) wereempirically administered after sampling blood for culture,
and an emergency operation was performed. The surgical
procedure included fasciotomy and extensive debridement
of the devitalized soft tissue along the lateral side of the
tibialis anterior of the affected leg, from the level below the
knee joint to the ankle joint. The excised devitalized soft
tissue disclosed suppurative necrosis on histopathology. The
administered antibiotics were switched to ciprofloxacin
(1200 mg/day parenterally).
Although it was hemodynamically stable after surgery, his
left leg did not make a favorable clinical response. The non-
excised skin andmuscles around the surgical site of his left leg
were poorly perfused. On day 4 of hospitalization, cultures of
bloodandexcisednecrotic tissue sampledduring theoperation
both yielded Gram-negative rods, which were identified as S.
putrefaciens by ID 32 GN (bioMe´rieux Vitek, Inc., Hazelwood,
MO, USA). Susceptibility testing using VITEK I automated
system (bioMe´rieux Vitek, Inc.) indicated that the isolated
microbe was susceptible to aztreonam, ampicillin/sulbactam,
piperacillin/tazobactam, ceftazidime, ceftriaxone, ciproflox-
acin, levofloxacin, imipenem, gentamicin, and amikacin. To
definitively identify the isolated pathogen, the partial 16S
rRNA gene was sequenced by PCR amplification using a uni-
versal forward primer 27F (50-AGAGTTTGATCCTGGCTCAG-30)7
and a universal reverse primer 907R (50-CCGTCAATTCCTTT-
GAGTTT-30),8 as previously described.7,8 Two harvested DNA
each with 881 and 895 nucleotides were sequenced by 310
Genetic Analyzer (Applied Biosystems) and were compared
to those available in the GenBank database (http://
www.ncbi.nlm.nih.gov/BLAST/BLAST.cgi); they were found
to be a 100% match with those of S. algae.
With regards to susceptibility, Etest on this S. algae isolate
was performed in accordance with the instructions of the
manufacturer (AB Biodisk, Solna, Sweden). The selected
antimicrobials (minimum inhibitory concentrations (MICs)
in mg/ml) were as follows: cephalothin (>256), cefotaxime
(0.19), ceftriaxone (0.25), ceftazidime (0.25), cefepime
(0.047), ciprofloxacin (0.19), levofloxacin (0.25), ampicil-
lin/sulbactam (0.75), piperacillin/tazobactam (0.125), erta-
penem (0.38), imipenem (6), and meropenem (0.38).
Ciprofloxacin was continued because of its favorable MIC.
In spite of antimicrobial use, progressive clinical dete-
rioration was observed. The patient received two further
debridement procedures in the affected leg, and as a result,
a considerable portion of skin and muscles in his left leg was
excised. All the excised tissues were suppuratively necrotic
by histopathology. Because of persistent deterioration, his
left leg was amputated from the level of above-knee joint on
hospitalization day 16. Thereafter his course was uneventful,
and the patient was discharged on day 31.
PubMed search and literature review
We performed a PubMed search for reports on Shewanella
infections that have been published since 1966 using the
keywords ‘Shewanella algae’, ‘Shewanella alga’, ‘Shewa-
nella putrefaciens’ and ‘Pseudomonas putrefaciens’ (the
previous name for Shewanella putrefaciens), and limited
the search to the English literature and adult humans. A
total of 27 adults (mean age 61.1  16.0 years) with soft
tissue infections caused by S. algae, S. alga, S. putrefaciens
or P. putrefacienswere found.9—27 Demographic, clinical, and
Table 1 Demographic, clinical, and laboratory characteristics of human soft tissue infections caused by Shewanella speciesa
No./sex/age (y) Underlying disease/condition Bacteria (source) (Method of identification) Affected site Prescribed antibiotic(s) 
debridement
Seawater
exposureReference
1/F/82 Malnutrition, leg edema and ulcers Pseudomonas putrefaciens,
CoNS (wound) (Conventional method)
Both legs Co-trimoxazole Unknown
9, 10b
2/F/73 Anemia, renal failure, bilateral leg ulcers Pseudomonas putrefaciens
(blood and wound), Pseudomonas
aeruginosa, Staphylococcus aureus
(wound) (Conventional method)
Both legs ulcers Ampicillin, gentamicin Unknown
11
3/F/60 Congestive heart failure, leprosy Pseudomonas putrefaciens, Escherichia
coli, Klebsiella pneumoniae, Proteus
mirabilis, Moraxella spp (wound)
(Unknown)
Left wrist, left leg Co-trimoxazole Unknown
12
4/M/63 Leg ulcers, congestive heart failure,
alcoholic liver cirrhosis, gouty arthritis
Pseudomonas putrefaciens
(blood/wound), CoNS, Enterobacter
agglomerans, Pseudomonas fluorescens
(wound) (API 20Ec)
Chronic ulcers on legs Gentamicin,
chloramphenicol;
co-trimoxazole,
debridement
Unknown
13
5/F/67 Hypothyroidism, hypertension, stasis
ulcers of both legs, right arm edema
and ecchymosis
Pseudomonas putrefaciens, group
A streptococcus (blood) (API 20E)
Both legs Nafcillin, penicillin,
gentamicin
No
14
6/F/34 Laurence—Moon—Bardet—Biedl
syndrome, renal failure on dialysis,
retinal pigmentation, blindness,
hypogonadism, obesity
Pseudomonas putrefaciens (blood)
(Conventional method, API Rapid
NFT systemc)
Both legs Mezlocillin, gentamicin Unknown
15
7/M/39 Prosthetic aortic valve infective
endocarditis, chronic leg edema
Pseudomonas putrefaciens, group
G streptococci (blood) (API 20E)
Left leg Ceftazidime Yes
15
8/M/75 Chronic angina, left leg edema
secondary to saphenous vein harvest
Pseudomonas putrefaciens
(blood) (VITEKc)
Left leg Piperacillin, ampicillin Yes
16
9/M/68 COPD, venous stasis, steroid use Shewanella putrefaciens
(blister aspirates) (API 20NEc)
Left ankle ulcer Flucloxacillin, penicillin,
cefotaxime, vancomycin
No
17
10/NA/75 Diabetic leg ulcer Shewanella putrefaciens
(blood) (API 20NE)
Leg ulcer NA Unknown
18
11/NA/57 Traumatic ulcer of lower
extremity, tetanus
Shewanella putrefaciens
(blood) (API 20NE)
Leg ulcer NA Unknown
18
12/NA/36 Traumatic ulcer of lower
extremity, cellulitis
Shewanella putrefaciens, Serratia
marcescens (blood) (API 20NE)
Leg ulcer NA Unknown
18
13/F/80 Rheumatoid arthritis, diabetes, arterial
insufficiency of the legs, leg ulcers
Shewanella alga (blood)
(Conventional method)
Left leg Ampicillin and gentamicin Unknown
19
14/M/69 Congestive heart failure, right leg ulcers Shewanella alga (blood/wound)
(Conventional method)
Right leg Penicillin and gentamicin;
ampicillin and gentamicin;
cefuroxime and gentamicin;
cefuroxime (oral), surgery
Unknown
19
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Table 1 (Continued )
No./sex/age (y) Underlying disease/condition Bacteria (source) (Method of identification) Affected site Prescribed antibiotic(s) 
debridement
Seawater
exposureReference
15/M/69 Chronic cholecystitis, cholelithiasis Shewanella putrefaciens, Escherichia
coli (pus) (ID 32 GNc)
Abdominal wall
infections and abscess
Ceftazidime and gentamicin;
cephalexin
Unknown
20
16/F/53 Aplastic anemia, steroid use, fish
puncture wound (finger)
Shewanella putrefaciens,
Staphylococcus aureus, viridans
streptococci (pus) (ID 32 GN)
Right middle finger Piperacillin and vancomycin Unknown
20
17/M/71 Obstructed nasolacrimal duct Shewanella putrefaciens,
Pseudomonas aeruginosa (pus) (ID 32 GN)
Dacryocystitis Cephalexin, drainage Unknown
20
18/M/53 Rectal cancer, intra-abdominal
carcinomatosis
Shewanella putrefaciens (pus) (ID 32 GN) Perineal abscess Ceftazidime and gentamicin Unknown
20
19/M/73 Alcoholism, fatty liver Shewanella putrefaciens (blood/wound)
(ID 32 GN)
Periorbital area Cefotaxime, clindamycin
and gentamicin
Unknown
20
20/M/61 COPD, vascular insufficiency of
the lower extremities
Shewanella putrefaciens (wound) (VITEK) Right foot abscess Ceftriaxone and clindamycin,
co-trimoxazole (oral), I/D
No
21
21/M/67 SLE, asthma, steroid use,
chronic leg ulcers
Shewanella putrefaciens
(wound) (API 20NE)
Left leg Penicillin and gentamicin,
ciprofloxacin (oral)
Yes
22
22/M/36 Healthy Shewanella putrefaciens,
Staphylococcus aureus, Enterococcus
faecalis (wound) (Unknown)
Both hands Flucloxacillin, ceftriaxone Yes
23
23/M/66 Multiple myeloma, renal insufficiency Shewanella alga (blood)
(API 20NE and GNIc)
Both forearms Ceftazidime, amikacin No
24
24/M/87 Cushingoid appearance Shewanella putrefaciens (blood)
(VITEK II3 and ID 32 GN)
Left forearm Ampicillin/sulbactam,
ampicillin (oral)
Yes
25
25/M/27 Healthy Shewanella putrefaciens
(wound) (ID 32 GN)
Scalp Ciprofloxacin, debridement Yes
26
26/F/67 Chronic renal failure on
maintenance hemodialysis
Shewanella putrefaciens (wound)
(VITEK, BBL Crystalc)
Left thigh Ceftazidime, minocycline,
oxacillin, fasciotomy,
debridement
No
27
27/M/42 Liver cirrhosis, hepatitis B Shewanella algae (blood/wound)
(Identification of 16S rDNA sequence)
Left leg Ciprofloxacin, debridement Yes
Current case
M, male; F, female; CoNS, coagulase-negative staphylococci; COPD, chronic obstructive pulmonary disease; SLE, systemic lupus erythematosus; NA, not available.
All patients survived except for patient cases 5 and 19 who died of sepsis and patient case 18 who died of underlying diseases.
a Pseudomonas putrefaciens is the previous name for Shewanella putrefaciens and Shewanella alga is the previous name for Shewanella algae.
b Case No. 1 was separately reported in two different articles.
c ID 32 GN, API 20E, API 20NE, VITEK, VITEK II, API Rapid NFT system, GNI, and BBL Crystal are commercial devices, which were used manually, semi-automatically, or automatically for the
identification of bacteria.
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Table 1.
Of the 27 patients with soft tissue infections, limb invol-
vement (18 lower and four upper limbs) was found in 22
(81.5%), while scalp, face, perineum, lacrimal sac, and
abdominal wall involvement were each found in one patient.
With regard to the leading underlying diseases/conditions,
chronic ulcer over the leg (14 cases (51.9%)) resulting from a
variety of causes including venous stasis, arterial insuffi-
ciency, diabetic foot, chronic leg edema, or traumatic
wounds was most commonly found, followed by steroid use
(four cases (14.8%)) and liver cirrhosis (three cases (11.1%)).
Shewanella bacteremia was found in 14 of the 22 patients
with soft tissue infections involving the limbs (11 cases of
monomicrobial bacteremia and three of polymicrobial bac-
teremia), and in one of the five cases of soft tissue infection
involving other anatomic sites. Overall, two patients died of
septicemia, giving a mortality rate of 7.4%.
Discussion
Out of more than 30 already known Shewanella species, only
S. putrefaciens and S. algae are considered pathogenic for
humans.2 The reason why S. algae causes more infections in
humans than S. putrefaciens is not fully understood. Some
investigators have hypothesized that the bacterial hemolysin
produced by the culprit S. algae plays an important role in the
pathogenesis of human infection.17
Remarkably, in addition to a variety of immunocompromis-
ing conditions, a preexisting chronic ulcer over the lower limb
was found in more than 50% of the affected patients. Because
Shewanella species normally exist in themarine environment,
the cutaneous breaches on the legs of these immunocompro-
mised patients served as a portal of entry for the opportunistic
pathogens during their recreational activities.
Unlike the previously reported cases of Shewanella soft
tissue infections, our case was clinically fulminant and
resembled the rapidly progressive soft tissue infections
caused by Vibrio vulnificus28 and Aeromonas species,29 which
are characterized by the emergence of bullae and rapid
development of progressive necrotizing fasciitis and septic
shock. The clinical manifestations of this case suggest that
when it comes to the etiology for a severe soft tissue infec-
tion, S. algae, V. vulnificus, and Aeromonas spp should all be
included in the differential diagnosis. The possibility that the
initial debridement was inadequate in our patient cannot be
excluded in view of the fact that deterioration subsequently
developed rapidly under prompt and aggressive surgery in
combination with effective antibiotics.
Earlier studies have demonstrated that aminoglycosides,
levofloxacin, third- and fourth-generation cephalosporins,
piperacillin, and carbapenems are active in vitro against
S. putrefaciens.30,31 The antimicrobial susceptibilities of
our clinical isolate were similar to those described pre-
viously.25,31 Of note, imipenem had a higher MIC against
the clinical Shewanella isolates than meropenem, as has
been shown in other reports.30,31 In terms of antimicrobial
susceptibility, some Shewanella isolates are intrinsically
resistant to imipenem,31 while some that were originally
susceptible to imipenem may develop resistance to this
antibiotic after clinical exposure to it.32 A chromosome-
encoded carbapenem-hydrolyzing Amber class D b-lactamaseharbored by the microbes has been reported to be respon-
sible for the high MIC of imipenem against S. algae isolates.31
Further study is warranted to clarify the role of empirical
treatment with a carbapenem in soft tissue infections in
patients with marine exposure.
Given the possible catastrophic consequences, education
on the prevention of Shewanella soft tissue infections in at-
risk people (e.g., the immunocompromised or elderly with a
cutaneous ulcer) relating the need to avoid exposure to the
marine environment or seawater may be of importance.
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